Recent Updates
Recently added Catalysts

CFZ533

Phase 2

Type 1 Diabetes Mellitus | Small molecule | Metabolic |Novartis AG|Last Updated: Apr 8, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment44
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04129528Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult SubjectsPHASE2 COMPLETED 44Nov 8, 2019Jun 4, 2024Apr 8, 202512 Belgium, Germany +4
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period
Adverse events were reported from first dose of study treatment to 98 days after last dose, up to a maximum duration of approximately 65 weeks.

Number of participants with treatment emergent AEs (any AE regardless of seriousness), AEs led to study treatment discontinuation, and SAEs. On-treatment period is defined as from date of first administration of study treatment to 98 days after date of last administration of study treatment (including start and stop date).

Normalized Stimulated C-peptide Area Under the Curve (AUC) at Week 52
At Week 52, 10 min prior to ingestion, at start of ingestion, and at 15, 30, 60, 90, and 120 min after consumption of the liquid meal.

The mixed meal tolerance test (MMTT) has appropriate sensitivity to detect residual insulin secretion and beta cell function. In the MMTT, following an 8-10 hour overnight fast, a weight-based liquid meal provided as 6 mL/kg (maximum 360 mL) of mixed meal, ingested over 5 min with timed blood samples for glucose and C peptide determination obtained 10 min prior to ingestion (t = -10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 min after consumption of the liquid meal. The time collections for post load samples are based on the start time of the mixed meal. Stimulated C-peptide AUC by the standard MMTT, normalized by the duration of measurements, was analyzed with a mixed model repeated measures analysis.

Secondary Endpoints
Maximum Plasma Concentration (Cmax) of CFZ533 After Intravenous (IV) Administration
Day 1: Pre-dose and 90 minutes after the start of the IV infusion (duration of the infusion is 30 minutes).
Trough Plasma Concentration (Ctrough) of CFZ533
Pre-dose at: Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56, Week 60, Week 64, Week 68, Week 72.
Time to Reach Maximum Plasma Concentration (Tmax) of CFZ533 After IV Administration
Day 1: Pre-dose and 90 minutes after the start of the IV infusion (duration of the infusion is 30 minutes).
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
CFZ533ACTIVE_COMPARATORRandomized in a 2:1 ratio: 2 Active / 1 Placebo
PlaceboPLACEBO_COMPARATORSimilar in appearance to active study drug
Interventions
NameTypeDescription
CFZ533DRUGFirst dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
PlaceboOTHERPlacebo for active drug
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 21 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: 1. Written informed consent, and if needed assent from the child on the trial, must be obtained before any assessment is performed. 2. Males and females aged between 12 and 21 years (inclusive, and enrolled in stages) at screening. 3. Body weight range from 30 to 125 kg (inclusi...

Countries:BelgiumGermanyItalySloveniaSpainUnited Kingdom
Unlock Eligibility Criteria